Ömer FaruK Saz

Dr. Ömer FaruK Saz

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2025 in Epilepsy Research
Verified
Journal Article
Closed access
BDBetül Diler Durgut
Betül Diler Durgut
BDBeril Dilber
Beril Dilber
TKTülay Kamaşak
Tülay Kamaşak
HYHüseyin Yaman
Hüseyin Yaman
ÖSÖmer FaruK Saz
Ömer FaruK Saz
ACAli Cansu
Ali Cansu

7 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AMali osman Metintas
ali osman Metintas
HYHüseyin Yaman
Hüseyin Yaman
LSLeyla baykal selçuk
Leyla baykal selçuk
AFArzu Ferhatosmanoğlu
Arzu Ferhatosmanoğlu
MDMAHİR DIĞIŞ
MAHİR DIĞIŞ
ÖSÖmer FaruK Saz
Ömer FaruK Saz
Background/Objective: Psoriasis is a chronic immune-mediated inflammatory disease with systemic involvement. Immature granulocytes (IGs) are potential inflammatory markers, but their role in psoriasis is unclear. We evaluated immature granulocyte count (IG#) and percentage (IG%) in plaque psoriasis, their associations with disease severity and treatment response, and their ability to distinguish patients from healthy controls. Methods: This retrospective study included 85 adults with plaque psoriasis and 85 healthy controls. Severity was assessed by the Psoriasis Area and Severity Index (PASI). IG#, IG%, and inflammatory markers were measured before treatment and after at least 3 months of systemic therapy. Group comparisons, correlations, and receiver operating characteristic (ROC) analyses were performed. Results: Pre-treatment IG# and IG% were higher in patients than in controls (both p < 0.001). IG# decreased after treatment (p = 0.004), whereas IG% did not (p = 0.072). Despite clinical improvement, post-treatment IG#, IG%, and C-reactive protein remained higher than controls. Pre-treatment IG# correlated weakly with PASI (r = 0.24, p = 0.020), whereas other PASI–IG correlations were non-significant. Discriminatory performance was modest for IG# (AUC = 0.697) and IG% (AUC = 0.658). Conclusions: IG# and IG% are elevated in plaque psoriasis. IG# decreases with treatment and may be a potential marker of inflammatory changes, while the persistence of elevated IG# and IG% levels after treatment relative to healthy controls may reflect residual inflammation. However, weak associations with disease severity and modest discriminatory performance do not support their use as standalone clinical tools. As these parameters are routinely available from complete blood counts, they may complement clinical assessment. Further prospective studies are required to establish their clinical relevance.